Ziopharm Oncology Inc. (NASDAQ:ZIOP)’s share price shot up 2.2% during mid-day trading on Tuesday . The stock traded as high as $6.14 and last traded at $5.99, with a volume of 1,367,637 shares changing hands. The stock had previously closed at $5.86.

Several brokerages have recently issued reports on ZIOP. Vetr upgraded Ziopharm Oncology from a “buy” rating to a “strong-buy” rating and set a $9.76 price target on the stock in a research note on Monday, April 25th. Raymond James Financial Inc. began coverage on Ziopharm Oncology in a research report on Thursday, June 2nd. They set a “market perform” rating on the stock. Wells Fargo & Co. restated a “sell” rating and set a $6.50 price objective on shares of Ziopharm Oncology in a research report on Thursday, May 12th. Zacks Investment Research upgraded Ziopharm Oncology from a “sell” rating to a “hold” rating in a research report on Wednesday, May 11th. Finally, Mizuho boosted their price objective on Ziopharm Oncology from $6.00 to $7.00 and gave the stock a “neutral” rating in a research report on Wednesday, May 11th. Four equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $9.75.

The company’s market cap is $768.62 million. The company’s 50 day moving average price is $5.29 and its 200-day moving average price is $6.75.

Ziopharm Oncology (NASDAQ:ZIOP) last posted its earnings results on Tuesday, August 9th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.90. The business earned $1.70 million during the quarter, compared to analysts’ expectations of $1.52 million. Ziopharm Oncology’s quarterly revenue was up 525.0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.11) EPS. Equities research analysts expect that Ziopharm Oncology Inc. will post ($1.15) earnings per share for the current fiscal year.

Several large investors recently bought and sold shares of ZIOP. California Public Employees Retirement System increased its stake in Ziopharm Oncology by 567.2% in the fourth quarter. California Public Employees Retirement System now owns 307,366 shares of the biotechnology company’s stock valued at $2,554,000 after buying an additional 261,300 shares in the last quarter. Morgan Stanley increased its stake in shares of Ziopharm Oncology by 5.1% in the fourth quarter. Morgan Stanley now owns 1,618,205 shares of the biotechnology company’s stock worth $13,447,000 after buying an additional 78,583 shares during the period. Finally, Swiss National Bank increased its stake in shares of Ziopharm Oncology by 2.2% in the fourth quarter. Swiss National Bank now owns 159,220 shares of the biotechnology company’s stock worth $1,323,000 after buying an additional 3,500 shares during the period.

ZIOPHARM Oncology, Inc is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.